https://doi.org/10.4081/ecj.2026.14934
A rapidly progressive rash with mucosal involvement
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 2 July 2026
A 40-year-old man, recently diagnosed with systemic lupus erythematosus, presented to the emergency department with a one-week history of high fever, headache, cough, and keratoconjunctivitis. Two weeks earlier, he had started treatment with hydroxychloroquine 200 mg twice daily (400 mg/day orally). After the onset of fever, he self-administered paracetamol 1 g three times daily. Within 48 hours, a rapid worsening of pre-existing cutaneous lesions occurred. Macular lesions rapidly coalesced into large flaccid blisters involving the face, chest, palms, and soles. The lesions exfoliated within three days. The patient reported severe pain affecting the skin and the mucous membranes of the mouth, genitals, and eyes. A positive Nikolsky sign was observed. On admission, he was febrile (38.5°C), with blood pressure 100/70 mmHg, heart rate 100 bpm, and respiratory rate 25 breaths per minute. Cutaneous detachment with areas of necrosis involved approximately 8% of the body surface area, predominantly involving the extremities, particularly the hands. Within a few days, all the lesions became necrotic. Laboratory tests showed leukocytosis and elevated C-reactive protein, while procalcitonin was negative. Pain severity was rated 9/10 on a visual analogue scale, requiring intravenous tramadol 100 mg every 8 hours for analgesia.
Downloads
1. Watanabe Y, Hama N. Recent advances in the diagnosis and treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis. Allergol Int 2025;74:345-55. DOI: https://doi.org/10.1016/j.alit.2025.05.008
2. Shah H, Parisi R, Mukherjee E, et al. Update on Stevens-Johnson syndrome and toxic epidermal necrolysis: diagnosis and management. Am J Clin Dermatol 2024;25:891-908. DOI: https://doi.org/10.1007/s40257-024-00889-6
3. Jacobsen A, Olabi B, Langley A, et al. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. Cochrane Database Syst Rev 2022;3:CD013130. DOI: https://doi.org/10.1002/14651858.CD013130.pub2
4. Stewart TJ, Farrell J, Frew JW. A systematic review of case-control studies of cytokines in blister fluid and skin tissue of patients with Stevens Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol 2024;65:491-504. DOI: https://doi.org/10.1111/ajd.14329
5. Nazerian A, Jafarzadeh A, Salehi S, et al. Cyclosporin for the treatment of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): a systematic review of observational studies and clinical trials focusing on single therapy, combination therapy, and comparative assessments. Inflammopharmacology 2025;33:485-503. DOI: https://doi.org/10.1007/s10787-024-01590-0
6. Justice J, Mukherjee E, Martin-Pozo M, Phillips E. Updates in the pathogenesis of SJS/TEN. Allergol Int 2025;74:361-71. DOI: https://doi.org/10.1016/j.alit.2025.05.002
7. Hasegawa A, Abe R. Stevens-Johnson syndrome and toxic epidermal necrolysis: Updates in pathophysiology and management. Chin Med J (Engl) 2024;137:2294-307. DOI: https://doi.org/10.1097/CM9.0000000000003250
8. Sadeghi Dousari A. Toxic shock syndrome: TSS — a comprehensive review. Infect Dis Clin Pract 2025;33:1471. DOI: https://doi.org/10.1097/IPC.0000000000001471
Ethics Approval
CRediT authorship contribution
All the authors equally contributed to the work and approved the final version.
Data Availability Statement
The datasets used during the current case report are available from the corresponding author on reasonable request.
How to Cite

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.




